CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (7,159,464)	$ (15,316,292)
Adjustments to reconcile net loss to net cash used by operating activities:
Non-cash compensation	994,981	1,006,960
Depreciation and amortization	494,996	414,115
Amortization of debt costs	107,604	79,338
Bad debt recoveries	(77,636)	(44,186)
Stock-based compensation	2,863,805	1,174,755
Foreign currency transaction (gain) loss	(1,416,577)	1,051,854
Changes in operating assets and liabilities:
Grants and accounts receivable	(1,083,938)	408,783
Inventories	128,727	(964,478)
Prepaid expenses and other current assets	1,104,461	(43,645)
Other assets	0	4,047
Accounts payable and accrued expenses	(512,439)	(405,820)
Net cash used by operating activities	(4,555,480)	(12,634,569)
Cash flows from investing activities:
Purchases of property and equipment	(546,389)	(557,411)
Payments for patent costs	(863,693)	(559,483)
Net cash used by investing activities	(1,410,082)	(1,116,894)
Cash flows from financing activities:
Equity contributions-net of fees	80,214,008	0
Fees related to equity facility	0	(87,881)
Proceeds from long-term debt	1,410,900	5,000,000
Repayment of long-term debt	(1,410,900)	0
Payment of debt acquisition costs	0	(4,212)
Proceeds from exercise of stock options	1,282,262	728,507
Proceeds from exercise of warrants	0	1,768,491
Net cash provided by financing activities	81,496,270	7,404,905
Effect of exchange rates on cash	215,217	(44,336)
Net change in cash and cash equivalents	75,745,925	(6,390,894)
Cash and cash equivalents - beginning of period	12,232,418	22,368,837
Cash and cash equivalents - end of period	87,978,343	15,977,943
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	883,857	732,537
Supplemental disclosure of non-cash financing activities
Settlement of accrued bonuses with restricted stock units	$ 657,780	$ 425,639